Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The oil and gas exploration company with interests in the BNG Conract Area in the Pre Caspian basin in Western Kazakhstan reports that a further approximately $7m has been received in connection with the disposal BNG Contract Area's shallow MJF and South Yelemes structures bringing the total received to date to approximately $69.1m of the $88m total consideration.</li>
<li>Formal completion of the Disposal is expected before the end of August 2025, following the transfer of various operational consents and licences.</li>
<li>Of the remaining approximately $18.9m due, approximately $5.1m is due to be received over a 12 month period commencing 6 months after formal completion and a further $13.8m is due to be received quarterly over the next 5 years to match the obligations relating to the remainder of the original $32m MJF Historic Costs assessment.</li>
</ul>


The oil and gas exploration company with interests in the BNG Conract Area in the Pre Caspian basin in Western Kazakhstan reports that a further approximately $7m has been received in connection with the disposal BNG Contract Area's shallow MJF and South Yelemes structures bringing the total received to date to approximately $69.1m of the $88m total consideration.
Formal completion of the Disposal is expected before the end of August 2025, following the transfer of various operational consents and licences.
Of the remaining approximately $18.9m due, approximately $5.1m is due to be received over a 12 month period commencing 6 months after formal completion and a further $13.8m is due to be received quarterly over the next 5 years to match the obligations relating to the remainder of the original $32m MJF Historic Costs assessment.


<ul>
<li>The UK drug delivery company focused on the localised delivery of chemotherapy drugs, announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer.</li>
<li>The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the AIM market last year and which highlighted the potential of ChemoSeed in multiple disease areas.</li>
<li>The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. </li>
</ul>


The UK drug delivery company focused on the localised delivery of chemotherapy drugs, announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer.
The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the AIM market last year and which highlighted the potential of ChemoSeed in multiple disease areas.
The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. 


United Kingdom

Personal Group Holdings provides workforce benefits, employee insurance, and reward technology in the United Kingdom. The company specializes in improving employee health, well-being, and engagement by offering services such as the Hapi platform and bespoke insurance products. Headquartered in Milton Keynes, the United Kingdom, the company was founded in 1996.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Personal Group Holdings (PGH LN)

Hybridan Small Cap Feast: 23/07/2025

Formal completion of the Disposal is expected before the end of August 2025, following the transfer of various operational consents and licences.

Hybridan

Hybridan Small Cap Feast: 27/03/2025

The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'.

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)